Viewing data from:

CONZIP

NDA

TRAMADOL HYDROCHLORIDE | N022370 | CIPHER PHARMACEUTICALS INC

4 strengths0 unique patents0 unique exclusivities

PTAB Proceedings

No IPR/PGR/CBM challenges found at the Patent Trial and Appeal Board

Patent Reexaminations

No ex parte or inter partes reexamination proceedings found at USPTO

Hatch-Waxman Litigation

No ANDA patent litigation cases (NOS 835) matched from PACER

Citizen Petitions

No FDA citizen petitions matched from Regulations.gov

Clinical Trials

167 trials from ClinicalTrials.gov — 2 recruiting, 1 active, 128 completed

Trial	Phase	Status	Sponsor	Enrollment	Dates
Tramadol Versus Placebo and Morphine in the Management of Post-Operative Pain Abdominoplasty NCT03774836	Phase 3	Active	Avenue Therapeutics, Inc.	360	2018-12-14 → 2019-06-30
Nephrostomy Tract Infiltration for Pain Control After PCNL NCT07721571	N/A	Recruiting	Hitit University	60	2026-07-17 → 2027-06-11
NonNarcotic Pain Control in Percutaneous Needle Tenotomy of Elbow NCT06373978	Phase 4	Recruiting	The Cleveland Clinic	92	2024-08-12 → 2027-06-30
Analgesic Equivalence of NSAIDs and Tramadol in Acute Postoperative Pain Following Minimally Invasive Surgery NCT07500454	N/A	Completed	ISSSTE Hospital Regional "Gral. Ignacio Zaragoza"	30	2024-06-20 → 2024-07-26
Effect of Preoperative Tramadol and Naproxen Sodium on Post Operative Pain NCT05982392	Phase 2/3	Completed	Dow University of Health Sciences	139	2023-03-01 → 2023-08-15
A Study to Compare the Bioavailability of Two Tramadol Hydrochloride Tablet Products (50 mg and 200 mg, Respectively) at Steady-state Under Fasting Conditions NCT00834288	Phase 1	Completed	Labopharm Inc.	26	2003-06
A Study to Compare the Relative Bioavailability of Two 200 Mg Tramadol Hydrochloride Tablet Products Under Fasting Conditions NCT00834366	Phase 1	Completed	Labopharm Inc.	26	2005-02 → 2005-03
Effect of Increased Pain Tolerance on Exercise Performance NCT03934411	N/A	Completed	University of Copenhagen	16	2018-03-01 → 2019-03-07
Conscious Sedation Efficacy of the MKO Melt (Midazolam, Ketamine, Ondansetron)NCT03653520	N/A	Completed	Avanti Anesthesia	651	2017-06-28 → 2017-11-04
Study to Evaluate the Effects of Tramadol Hydrochloride on Cardiac Repolarization in Healthy Participants NCT02307864	Phase 1	Completed	Janssen Scientific Affairs, LLC	68	2014-12-04 → 2015-08-27

Source: ClinicalTrials.gov. Trials matched by ingredient name; data refreshed each weekday and may lag the registry.

Drug Pricing (NADAC)

National Average Drug Acquisition Cost — Week of 2026-08-26 | 2 NDCs

Highest NADAC/Unit

$9.36

per ea

Lowest NADAC/Unit

$7.79

per ea

Brand NDCs

Generic NDCs

NDC Description	NADAC/Unit	Unit	Type	Generic NADAC	Effective
13811069030TRAMADOL HCL ER 200 MG CAPSULE	$9.36	EA	Generic	—	2026-08-19
13811068930TRAMADOL HCL ER 100 MG CAPSULE	$7.79	EA	Generic	—	2026-08-19

Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.

VA Federal Supply Schedule

Government-negotiated contract prices | 12 NDCs (6 FSS, 6 Big4)

Lowest Price

$65.86

Highest Price

$672.54

FSS NDCs

Big4 NDCs

Description	Price	Type	Vendor	Contract End
13811-0689-30TRAMADOL HCL 100MG CAP,SA	$230.73	Big4	Avion Pharmaceuticals, LLC	12/31/2026
13811-0689-30TRAMADOL HCL 100MG CAP,SA	$230.73	FSS	Avion Pharmaceuticals, LLC	12/31/2026
13811-0690-30TRAMADOL HCL 200MG CAP,SA	$138.31	Big4	Avion Pharmaceuticals, LLC	12/31/2026
13811-0690-30TRAMADOL HCL 200MG CAP,SA	$302.37	FSS	Avion Pharmaceuticals, LLC	12/31/2026
13811-0691-30TRAMADOL HCL 300MG CAP,SA	$179.07	Big4	Avion Pharmaceuticals, LLC	12/31/2026
13811-0691-30TRAMADOL HCL 300MG CAP,SA	$418.25	FSS	Avion Pharmaceuticals, LLC	12/31/2026

Showing 6 of 12 NDCs.

Source: VA Federal Supply Schedule (va.gov). Prices are government-negotiated contract prices.

Medicare Part D Spending

CMS annual spending data for Conzip (2024)

Total Spending

$41K

Total Claims

Beneficiaries

Avg Cost/Unit

$15.42

Spending Trend

$181K(2019)→$121K(2020)→$104K(2021)→$50K(2022)→$42K(2023)→$41K(2024)

YoY Change:+0.1%

5yr CAGR:+1.8%

Source: CMS Medicare Part D Spending by Drug (2024). Shows gross drug cost under Part D.

API Supply Chain19 active DMFs20 inactive

16 active API suppliers hold Drug Master Files for this ingredient.

WAVELENGTH ENTERPRISES LTDTRAMADOL HYDROCHLORIDE

DMF 119591996

SUN PHARMACEUTICAL INDUSTRIES LTDTRAMADOL HYDROCHLORIDE USP

DMF 160022002

ZYDUS LIFESCIENCES LTDTRAMADOL HYDROCHLORIDE USP

DMF 170372004

PROTO CHEMICALS AGTRAMADOL HYDROCHLORIDE

DMF 171662004

WANBURY LTDTRAMADOL HYDROCHLORIDE

DMF 179702005

JUBILANT BIOSYS LTDTRAMADOL HYDROCHLORIDE USP

DMF 188032005

ARAGEN LIFE SCIENCES LTDTRAMADOL HYDROCHLORIDE

DMF 206322007

CSPC OUYI PHARMACEUTICAL CO LTDTRAMADOL HYDROCHLORIDE

DMF 218052008

RAKS PHARMA PVT LTDTRAMADOL HYDROCHLORIDE USP

DMF 231212009

APITORIA PHARMA PRIVATE LTDTRAMADOL HYDROCHLORIDE USP (NON STERILE DRUG SUBSTANCE)

DMF 242852010

PIRAMAL PHARMA LTDTRAMADOL HYDROCHLORIDE

DMF 249542011

RAKS PHARMA PVT LTDTRAMADOL HYDROCHLORIDE USP API (PROCESS-2)

DMF 271592013

VIRUPAKSHA ORGANICS LTDTRAMADOL HYDROCHLORIDE

DMF 305042016

UNICHEM LABORATORIES LTDTRAMADOL HYDROCHLORIDE USP

DMF 334242019

MACLEODS PHARMACEUTICALS LTDTRAMADOL HYDROCHLORIDE USP

DMF 336212019

SUN PHARMACEUTICAL INDUSTRIES LTDTramadol Hydrochloride USP (Process-II)

DMF 347452020

EMNAR PHARMA PRIVATE LTDTRAMADOL HYDROCHLORIDE USP

DMF 354452021

SUPRIYA LIFESCIENCE LTDTRAMADOL HYDROCHLORIDE USP

DMF 395332024

SUPRIYA LIFESCIENCE LTDTRAMADOL HYDROCHLORIDE USP-(PROCESS II)

DMF 412262025

NORAMCO DELAWARE INCInactiveTRAMADOL HYDROCHLORIDE

DMF 98071992

GRUNENTHAL GMBHInactiveTRAMADOL HYDROCHLORIDE

DMF 98111992

IROTEC LABORATORIESInactiveTRAMADOL HYDROCHLORIDE

DMF 115261995

HELSINN CHEMICALS SAInactiveTRAMADOL HYDROCHLORIDE

DMF 116051995

ZENTIVA ASInactiveTRAMADOL HYDROCHLORIDE

DMF 124041997

WYCKOFF CHEMICAL CO INCInactiveTRAMADOL HYDROCHLORIDE

DMF 128301998

EXCELLA GMBHInactiveTRAMADOL HYDROCHLORIDE

DMF 128691998

SHIJIAZHUANG PHARMACEUTICAL GROUP CO LTDInactiveTRAMADOL HYDROCHLORIDE USP (BULK)

DMF 143331999

EVONIK TECHNOCHEMIE GMBHInactiveTRAMADOL HYDROCHLORIDE

DMF 145411999

RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA SPAInactiveTRAMADOL HYDROCHLORIDE

DMF 147612000

DISHMAN PHARMACEUTICALS AND CHEMICALS LTDInactiveTRAMADOL HYDROCHLORIDE

DMF 156302001

DAI-ICHI KARKARIA LTDInactiveTRAMADOL HYDROCHLORIDE EP

DMF 174082004

SHIJIAZHUANG PHARMACEUTICAL GROUP HUASHENG PHARMA CO LTDInactiveTRAMADOL HYDROCHLORIDE EP

DMF 185782005

AREVIPHARMA GMBHInactiveTRAMADOL HYDROCHLORIDE

DMF 191172006

TONIRA PHARMA LTDInactiveTRAMADOL HYDROCHLORIDE

DMF 202042007

ZHEJIANG HISOAR PHARMACEUTICAL CO LTDInactiveTramadol Hydrochloride

DMF 212492007

IPCA LABORATORIES LTDInactiveTRAMADOL HYDROCHLORIDE USP

DMF 216792008

KAMUD DRUGS PVT LTDInactiveTRAMADOL HYDROCHLORIDE BP

DMF 219152008

CADILA HEALTHCARE LTDInactiveTRAMADOL HYDROCHLORIDE

DMF 226872009

IPCA LABORATORIES LTDInactiveTRAMADOL HYDROCHLORIDE (YT3 PROCESS)

DMF 247662011

Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.

Approval Letters

14 letters from Drugs@FDA

Date	Submission	Document
Jun 23, 2026	SUPPL -28	View Letter (PDF)
Dec 31, 2025	SUPPL -27	View Letter (PDF)
Nov 4, 2024	SUPPL -26	View Letter (PDF)
Dec 19, 2023	SUPPL -25	View Letter (PDF)
Sep 14, 2021	SUPPL -23	View Letter (PDF)
Mar 5, 2021	SUPPL -20	View Letter (PDF)
Oct 8, 2019	SUPPL -18	View Letter (PDF)
Oct 1, 2018	SUPPL -16	View Letter (PDF)
Oct 1, 2018	SUPPL -17	View Letter (PDF)
Aug 31, 2017	SUPPL -15	View Letter (PDF)
Dec 21, 2016	SUPPL -14	View Letter (PDF)
Dec 21, 2016	SUPPL -12	View Letter (PDF)
May 12, 2010	ORIG -1	View Letter (PDF)
Feb 18, 2009	ORIG -1	View Letter (PDF)

Source: Drugs@FDA application documents.

Products (4)

Sort:

#001 — 100MG

RLD

0 patents0 exclusivities▴

CAPSULE, EXTENDED RELEASE;ORAL | Approved: May 7, 2010

No patent or exclusivity listings for this strength.

#002 — 200MG

RLD

0 patents0 exclusivities▾

CAPSULE, EXTENDED RELEASE;ORAL | Approved: May 7, 2010

#003 — 300MG

RLD

0 patents0 exclusivities▾

CAPSULE, EXTENDED RELEASE;ORAL | Approved: May 7, 2010

#004 — 150MG

RLD

0 patents0 exclusivities▾

CAPSULE, EXTENDED RELEASE;ORAL | Approved: Aug 1, 2011